- Poster presentation
- Open Access
Time-resolved early-to-late Gadolinium enhancement MRI using single breath-hold 3D spiral imaging
© Shin et al; licensee BioMed Central Ltd. 2012
- Published: 1 February 2012
- Late Gadolinium Enhancement
- Late Gadolinium Enhancement Image
- Time Intensity Curve
- Scar Region
- Minute Post Injection
The assessment of myocardial infarction (MI) heterogeneity using late Gadolinium enhancement (LGE) MRI has been limited to static analysis at single late post-injection time. We developed a rapid single breath-hold LGE MRI method using a novel parallel imaging accelerated 3D spiral acquisition. We propose to use this technique to capture temporal variation in scar enhancement at early to late post-injection times, termed early-to-late Gadolinium enhancement (ELGE) MRI.
We developed an inversion recovery 3D spiral imaging sequence with a novel iterative self-consistent parallel imaging reconstruction (SPIRiT) method, which allows entire LV coverage within only 12 heart beats. The scan parameters were: acceleration factor = 2, TI=200-300ms, spatial resolution = 1.7×1.7×7 mm3, 14 partition slices, 190 ms data acquisition window at mid-diastole, a GE 1.5 T scanner, and an 8-channel cardiac coil. Starting at 1 or 2 minutes after contrast administration, the 3D ELGE imaging was performed every minute until 10 minutes post injection. Afterwards, the standard 2D multi-slice LGE MRI was performed. The time series of 3D ELGE data were registered using a mutual information-based motion correction to compensate for different breath-hold positions.
Time-resolved characterization of myocardial scar tissue is feasible using 3D spiral ELGE MRI. Visual assessment and ROI-based time curve analysis demonstrated that scar enhancement is heterogeneous both spatially and temporally. Clinical validation of the proposed ELGE MRI in a large cohort of MI patients remains to be investigated.
AHA postdoctoral fellowship (09POST2150025).
NIH SBIR grant (5R44HL084769).
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.